missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ CD153 Monoclonal Antibody (116615)

Mouse Monoclonal Antibody
Brand: Invitrogen™ MA561858
This item is not returnable.
View return policy
Description
Reconstitute at 0.5 mg/mL in sterile PBS.
The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and the IL4 receptor.
Specifications
| CD153 | |
| Monoclonal | |
| 0.5 mg/mL | |
| PBS with trehalose and no preservative | |
| P32971 | |
| Tnfsf8 | |
| Mouse myeloma cell line NS0-derived recombinant human CD30 Ligand/TNFSF8, Gln63-Asp234. | |
| 500 μg | |
| Primary | |
| Human | |
| Antibody | |
| IgG2a |
| Western Blot | |
| 116615 | |
| Unconjugated | |
| Tnfsf8 | |
| CD153; CD153 antigen; CD30 antigen ligand; CD30 ligand; Cd30l; CD30-L; Cd30lg; CD30ligand; Tnfsf8; TNLG3A; tumor necrosis factor (ligand) superfamily member 8; tumor necrosis factor (ligand) superfamily, member 8; tumor necrosis factor ligand 3A; tumor necrosis factor ligand superfamily member 8; tumor necrosis factor superfamily member 8 | |
| Mouse | |
| Protein A/G | |
| RUO | |
| 944 | |
| Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
| Lyophilized |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction